GILD · Insider Trading
Gilead Sciences Inc
Every open-market purchase and sale reported by GILD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$468.66K |
| 2026-10-16 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$468.66K |
| 2026-10-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | −15,000 | −$2.22M |
| 2026-09-23 | Erin Burkhart | SVP, Controllership | MIXED | +1,455 | −$117.25K |
| 2026-09-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$432.65K |
| 2026-09-16 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$435.87K |
| 2026-09-11 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | +1,450 | −$195.06K |
| 2026-09-11 | Andrew D Dickinson | Chief Financial Officer | MIXED | +1,450 | −$195.06K |
| 2026-09-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | +305 | −$41.27K |
| 2026-09-11 | Daniel Patrick O'Day | Chairman & CEO | MIXED | +4,550 | −$612.55K |
| 2026-09-11 | Dietmar Berger | Chief Medical Officer | MIXED | +270 | −$38.09K |
| 2026-09-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | −15,000 | −$2.23M |
| 2026-08-27 | Anthony Welters | Director | MIXED | — | −$1.58M |
| 2026-08-21 | Jeffrey Bluestone | Director | MIXED | — | −$389.87K |
| 2026-08-18 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$415.08K |
| 2026-08-18 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | −3,000 | −$2.18M |
| 2026-08-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | +3,094 | −$386.94K |
| 2026-08-04 | Daniel Patrick O'Day | Chairman & CEO | Sell | −15,000 | −$1.95M |
| 2026-07-16 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$389.78K |
| 2026-07-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$389.76K |
| 2026-07-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | −15,000 | −$1.89M |
| 2026-06-16 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$376.20K |
| 2026-06-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$371.76K |
| 2026-06-11 | Dietmar Berger | Chief Medical Officer | MIXED | +270 | −$31.95K |
| 2026-06-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | +306 | −$34.38K |
| 2026-06-11 | Daniel Patrick O'Day | Chairman & CEO | MIXED | +4,566 | −$511.80K |
| 2026-06-11 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | +1,455 | −$162.90K |
| 2026-06-11 | Andrew D Dickinson | Chief Financial Officer | MIXED | +1,455 | −$162.90K |
| 2026-06-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | −15,000 | −$1.97M |
| 2026-05-18 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | −3,000 | −$2.01M |
| 2026-05-18 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$396.81K |
| 2026-05-04 | Kelly A. Kramer | Director | A | +6,030 deriv. | — |
| 2026-05-04 | Harish Manwani | Director | MIXED | +922 | −$29.31K |
| 2026-05-04 | Anthony Welters | Director | A | +1,146 | — |
| 2026-05-04 | Javier Rodriguez | Director | A | +1,146 | — |
| 2026-05-04 | Ted W Love | Director | A | +1,146 | — |
| 2026-05-04 | Sandra Horning | Director | A | +1,146 | — |
| 2026-05-04 | Jacqueline K Barton | Director | A | +1,146 | — |
| 2026-05-04 | Jeffrey Bluestone | Director | A | +1,146 | — |
| 2026-04-29 | Daniel Patrick O'Day | Chairman & CEO | Sell | −10,000 | −$1.29M |
| 2026-04-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$422.88K |
| 2026-04-16 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$422.88K |
| 2026-03-30 | Daniel Patrick O'Day | Chairman & CEO | Sell | −10,000 | −$1.37M |
| 2026-03-17 | Andrew D Dickinson | Chief Financial Officer | Sell | −3,000 | −$432.69K |
| 2026-03-17 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | −3,000 | −$432.69K |
| 2026-03-12 | Dietmar Berger | Chief Medical Officer | MIXED | +1,070 | −$157.92K |
| 2026-03-12 | Daniel Patrick O'Day | Chairman & CEO | MIXED | +10,259 | −$1.45M |
| 2026-03-12 | Erin Burkhart | SVP, Controllership | A | +7,810 deriv. | — |
| 2026-03-12 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | +640 | −$90.03K |
| 2026-03-12 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | +3,401 | −$477.77K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel Patrick O'Day | Chairman & CEO | 569,683 | $88.89M |
| Andrew D Dickinson | Chief Financial Officer | 161,096 | $25.14M |
| Johanna Mercier | Chief Comm & Corp Aff Officer | 113,684 | $17.74M |
| Merdad Parsey | Chief Medical Officer | 84,621 | $13.20M |
| Diane E. Wilfong | Interim Corp Controller & CAO | 46,259 | $7.22M |
| Deborah H Telman | EVP, Corporate Affairs & GC | 43,676 | $6.82M |
| Sandra Patterson | SVP, Controllership | 40,077 | $6.25M |
| Jacqueline K Barton | Director | 27,202 | $4.24M |
| Dietmar Berger | Chief Medical Officer | 19,785 | $3.09M |
| Anthony Welters | Director | 19,774 | $3.09M |
| Harish Manwani | Director | 15,239 | $2.38M |
| Javier Rodriguez | Director | 13,364 | $2.09M |
| Jeffrey Bluestone | Director | 10,066 | $1.57M |
| Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | 9,044 | $1.41M |
| Sandra Horning | Director | 6,293 | $981.96K |
| Ted W Love | Director | 5,484 | $855.72K |
| Kelly A. Kramer | Director | 4,145 | $646.79K |
| Erin Burkhart | SVP, Controllership | 2,223 | $346.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GILD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.